Patents by Inventor Xiaohong She

Xiaohong She has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cancer using anti-CD137 antibody
    Patent number: 11859003
    Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: January 2, 2024
    Assignee: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li, Jun Chen, Xiaohong She, Peter Cheung
  • Anti-CSF1R Molecules and Use Thereof
    Publication number: 20230203170
    Abstract: The disclosure relates to antibodies against human CSF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 29, 2023
    Inventors: Fangyong Du, Peter Peizhi Luo, Yan Li, Guizhong Liu, Xiaohong She, Zhengxi Dai
  • ANTI-CD137 MOLECULES AND USE THEREOF
    Publication number: 20220204637
    Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Application
    Filed: December 28, 2021
    Publication date: June 30, 2022
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Fangyong DU, Yan LI, Guizhong LIU, Jun CHEN, Xiaohong SHE, Peter CHEUNG
  • Anti-CD137 molecules and use thereof
    Patent number: 11242395
    Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
  • ANTI-CD137 MOLECULES AND USE THEREOF
    Publication number: 20200369776
    Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 26, 2020
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU, Yan LI, Jun CHEN, Xiaohong SHE, Peter CHEUNG
  • ANTI-CD137 MOLECULES AND USE THEREOF
    Publication number: 20190055314
    Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung